EMEA-003273-PIP01-22 - paediatric investigation plan

cobolimab

Key facts

• Active Substance:
  cobolimab
• Therapeutic area:
  Oncology
• Decision number:
  P/0512/2022
• PIP number:
  EMEA-003273-PIP01-22
• Pharmaceutical form(s):
  All pharmaceutical forms
• Condition(s) / indication(s):
  Treatment of lung cancer
• Route(s) of administration:
  All routes of administration
• Contact for public enquiries:

  Glaxo Group Limited

  Tel. [phone]; E-mail: [e-mail]

• Decision type:
  W: decision granting a waiver in all age groups for all conditions or indications
• Decision date:
  02/12/2022

Decision

P/0512/2022: EMA decision of 2 December2022 on the granting of a product specific waiver for cobolimab (EMEA-003273-PIP01-22)

AdoptedReference Number: EMA/898523/2022